Type 2 Diabetes | Treatment Algorithms: Claims Data Analysis | US | 2017
Historically, biguanides and sulfonylureas were the most heavily prescribed T2D drug classes. However, the DPP-IV inhibitors have recently overtaken sulfonylureas to become the second-most heavily prescribed drug class. Numerous branded agents jostle for position as second-line treatment options, including the DPP-IV inhibitors, the SGLT2inhibitors Jardiance, Invokana and Farxiga, the GLP-1 receptor agonists Victoza and Trulicity, and the insulins. Adding to the complexity of the market dynamics, the biosimilar insulin Basaglar is also picking up significant patient share.
Questions answered:
- What patient share do key therapies and brands garner by line of therapy in newly diagnosed type 2 diabetes patients? What are the quarterly trends in prescribing among recently-treated and new diagnosed type 2 diabetes patients?
- What proportion of type 2 diabetes patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of type 2 diabetes patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
- What are the product-level compliance and persistency rates among drug-treated patients with type 2 diabetes?
Key analysis provided:
- Brand usage across longitudinal patient sample
- Newly diagnosed patient analysis
- Treatment initiation and progression
- Line of therapy analysis
- Combination therapy analysis
- Source of business for recently treated patients
- Persistency and compliance analysis
- Product-level patient flow charts
Markets covered: United States
Primary research: Longitudinal patient-level claims data analysis
Related Market Assessment Reports
Report
Chronic Pain – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Back Pain (US)
Approximately 30 million people in the United States have chronic back pain (CBP). Treatment of CBP poses a challenge to physicians owing to the heterogeneity of pain pathophysiology and the…
Report
Post-Traumatic Stress Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Post-Traumatic Stress Disorder (US)
Multiple guidelines recommend treating post-traumatic stress disorder (PTSD) first with psychotherapy. However, such approaches do not suffice for many patients, necessitating the use of…
Report
Postpartum Depression – Current Treatment – Treatment Algorithms: Claims Data Analysis – Postpartum Depression (US)
Postpartum depression (PPD) refers to depression experienced by women after childbirth. The PPD drug market consists of very limited treatment options specifically approved for PPD, so drugs used…
Report
Venous Thromboembolism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Venous Thromboembolism (US)
Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus. It consists of deep vein thrombosis (DVT) and pulmonary embolism (PE), depending on the vein affected. Current…
